Topical applications of an emollient reduce circulating pro-inflammatory cytokine levels in chronically aged humans: a pilot clinical study
Topical applications of an emollient reduce circulating pro-inflammatory cytokine levels in chronically aged humans: a pilot clinical study
复制标题
DOI：
10.1111/jdv.15540
复制
发表时间：
2019-11-01
影响因子：
9.2
通讯作者：
Man, M. Q.
中科院分区：
文献类型：
--
作者：
Ye, L.;Mauro, T. M.;Man, M. Q.
虽然在按时间顺序老化的人中循环炎性细胞因子水平的增加与衰老相关的慢性疾病（例如，然而，尽管这些疾病（例如，心血管疾病、II型糖尿病、骨质疏松症和阿尔茨海默病）的发病率较高，但减少循环细胞因子的方法尚不可用。在按时间顺序老化的小鼠中，我们最近证明，表皮功能障碍在很大程度上导致了循环细胞因子水平的年龄相关性升高，并且改善表皮功能降低了循环细胞因子水平。目的：我们进行了一项初步研究，以确定改善表皮功能是否会降低老年人循环中促炎细胞因子水平。方法33名老年人每天局部治疗两次，持续30天，使用约3 mL的润肤剂，以前显示可以改善表皮功能，而未经治疗的老年人和一组年轻志愿者作为对照。使用Luminex 200（TM）系统在基线和治疗后测量表皮功能的变化和三种关键的、年龄相关的血浆细胞因子（IL-1 β、IL-6和TNF α）的水平。结果我们还发现老年人IL-1 β、IL-6和TNF α的基线水平显著高于年轻人（P < 0.001）。局部应用屏障修复润肤剂显著增强表皮通透性屏障功能（P < 0.01）和角质层水合作用（P < 0.05）。同时，IL-1 β和IL-6的循环水平正常化，而TNF α水平大幅下降。结论该初步研究结果提示，应进行更大规模的临床试验，以证实改善表皮功能是否也可以降低老年人循环促炎细胞因子水平，同时可能减轻老年人慢性炎症性疾病的下游发展。
Background While increased levels of circulating inflammatory cytokines in chronologically aged humans have been linked to the development of ageing-associated chronic disorders (e.g., cardiovascular disease, type II diabetes, osteoporosis and Alzheimer's disease), approaches that reduce circulating cytokines are not yet available. In chronologically aged mice, we recently demonstrated that epidermal dysfunction largely accounts for age-associated elevations in circulating cytokine levels, and that improving epidermal function reduced circulating cytokine levels. Objective We performed a pilot study to determine whether improving epidermal function reduces circulating pro-inflammatory cytokine levels in aged humans. Methods Thirty-three aged humans were topically treated twice-daily for 30 days, with approximate to 3 mL of an emollient, previously shown to improve epidermal function, while untreated, aged humans and a cohort of young volunteers served as controls. Changes in epidermal function and levels of three key, age-related, plasma cytokines (IL-1 beta, IL-6 and TNF alpha) were measured at baseline and after treatment, using Luminex 200 (TM) system. Results We also found significantly higher baseline levels of IL-1 beta, IL-6 and TNF alpha in aged vs. young humans (P < 0.001), as previously reported. Topical applications of the barrier repair emollient significantly enhanced epidermal permeability barrier function (P < 0.01) and stratum corneum hydration (P < 0.05). In parallel, circulating levels of IL-1 beta and IL-6 normalized, while TNF alpha levels declined substantially. Conclusion The results of this preliminary study suggest that a larger clinical trial should be performed to confirm whether improving epidermal function also can reduce circulating pro-inflammatory cytokine levels in aged humans, while also possibly attenuating the downstream development of chronic inflammatory disorders in the aged humans.